1O
1OT.F Ovid Therapeutics Inc
- Market cap
- EUR 464M
- P/E
- -
- P/B
- 2.64x
- ROE
- -30.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1OT.F undervalued?
Graham numberThe Graham number of Ovid Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ovid Therapeutics Inc fundamental analysis
No fundamental analysis for Ovid Therapeutics Inc yet.
Ovid Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clini…
Full company profileOvid Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ovid Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 12.6M | 208M | 1.50M | 392K | 566K | 7.25M | 1.47M |
| Operating Income | -22.5M | -65.0M | -52.9M | -61.4M | -81.4M | 124M | -55.5M | -59.3M | -61.9M | -42.4M | -67.1M |
| EBITDA | - | -64.9M | -52.8M | -61.2M | -81.1M | 124M | -54.2M | -58.7M | -61.3M | -42.2M | -67.0M |
| Net Income | -22.4M | -64.8M | -52.0M | -60.5M | -81.0M | 123M | -54.2M | -52.3M | -26.4M | -17.4M | -64.0M |
| EPS | - | -2.63 | -2.11 | -1.11 | -1.23 | 1.75 | -0.77 | -0.74 | -0.37 | -0.13 | -0.35 |
| Balance Sheet | |||||||||||
| Total Assets | 53.0M | 89.5M | 47.6M | 80.8M | 75.9M | 195M | 155M | 144M | 92.2M | 151M | 232M |
| Total Liabilities | 3.73M | 6.02M | 8.84M | 10.8M | 32.3M | 14.8M | 23.0M | 56.2M | 23.9M | 20.3M | 22.1M |
| Shareholders' Equity | 49.3M | 83.4M | 38.8M | 70.0M | 43.6M | 180M | 132M | 87.8M | 68.2M | 131M | 210M |
| Cash & Short-term Investments | 51.9M | 87.1M | 36.5M | 41.9M | 72.0M | 188M | 129M | 27.0M | 26.3M | 13.2M | 11.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.8M | -31.5M | -45.6M | -51.1M | -51.6M | 119M | -55.2M | -45.8M | -56.0M | -38.3M | -63.0M |
| Capital Expenditure | 189K | 38.9K | 33.9K | 57.2K | 127K | 184K | 1.22M | 137K | 161K | 0.00 | 0.00 |
| Free Cash Flow | - | -31.5M | -45.9M | -51.3M | -52.0M | 118M | -56.6M | -45.9M | -56.1M | -38.3M | -63.0M |
| Ratios | |||||||||||
| ROE | -45.5% | -77.7% | -134.0% | -86.3% | -185.7% | 68.3% | -41.0% | -59.6% | -38.7% | -13.3% | -30.5% |
| ROA | -42.3% | -72.4% | -109.1% | -74.8% | -106.7% | 63.1% | -34.9% | -36.3% | -28.7% | -11.5% | -27.6% |
| Net Profit Margin | - | - | - | - | -642.3% | 58.9% | -3,604.7% | -13,351.8% | -4,670.1% | -240.1% | -4,365.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ovid Therapeutics Inc dividends
Ovid Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Ovid Therapeutics Inc
- Insiders 6.72%
- Institutions 81.64%
- Public & others 11.63%
- Shares outstanding 189M
- Free float 158M
Ovid Therapeutics Inc company profile
- Company name
- Ovid Therapeutics Inc
- Ticker
- 1OT.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Fiscal year end
- December
- Address
- Hudson Commons, New York, NY, United States, 10001
- Phone
- 646 661 7661
- Website
- ovidrx.com
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Ovid Therapeutics Inc management
10- Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.Co-Founder & Executive Chairman · born 1953
- Ms. Margaret AlexanderCEO, President & Director · born 1981
- Mr. Jeffrey A. RonaAdvisor · born 1968
- Mr. Charles Ross Carter M.B.A., M.S.CFO, Principal Financial Officer, Principal Accounting Officer & Secretary · born 1967
- Dr. Zhong Zhong Ph.D.Chief Scientific Officer
- Dr. Julia Tsai Ph.D.Senior Vice President of Clinical Development · born 1975
- Dr. Toshiya Nishi D.V.M.Head of Epilepsy Research
- Ms. Victoria FortChief Strategy Officer
- Dr. Petra Kaufmann M.D., M.S.Chief Medical Officer · born 1966
- Mr. Kevin Norrett M.B.A., M.S.Chief Business Officer · born 1973